top of page

Research Roundup: Mar 19, 2024

Best of cannabinoid science this week...

In people with Alzheimer's disease, a high-CBD/low-THC oil lowered anxiety & agitation symptoms

Caring for Behavioral Symptoms of Dementia (CBD): A New Investigation into Cannabidiol for the Treatment of Anxiety and Agitation in Alzheimer's Dementia

On treating migraines with a vape that contains 6% THC + 11% CBD

Vaporized Cannabis versus Placebo for Acute Migraine: A Randomized Controlled Trial

The National Animal Supplement Council releases a study on the safety of 90 days of CBD in dogs (hattip to Vandana Kothari, Director of Quality at CV Sciences)

Safety study of cannabidiol products in healthy dogs

National Animal Supplement Council Announces Publication of Landmark Safety Study of Cannabidiol Products in Healthy Dogs

And in a survey of Danish dog owners (where cannabis products for dogs are unlicensed), the majority confirmed the use of cannabinoids, most especially for pain, behavioral issues & allergy, with the most efficacy being for pain

Danish dog owners' use and the perceived effect of unlicensed cannabis products in dogs

In COVID-19 survivors with neuropsychiatric manifestations, those who used 1200 mg of ultramicronized PEA for three months showed greater improvements in their depression & fatigue than those who refused this treatment

Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors

And in children with irritable bowel syndrome, a combination of PEA & polydatin (a derivative of resveratrol) caused a significant reduction in abdominal pain, diarrhea & saw more patients achieving complete remission

Palmitoylethanolamide and polydatin in pediatric irritable bowel syndrome: A multicentric randomized controlled trial

From public health data on generalized anxiety disorder, initiating cannabis based medicines was associated with improved anxiety severity & general quality of life

UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients

On the characteristics of older cannabis users & why they used it

Characteristics of Older Adult Cannabis Users

“The majority, (83.3%) did not experience any adverse reactions from using cannabis but (16.7%) experienced adverse effects including dry mouth, paranoia, and forgetfulness. The most common conditions/symptoms reported were anxiety, pain/arthritis, insomnia, depression, headache, and nausea and vomiting. Patients deemed cannabis " Extremely helpful" in the relief of (41.7%) anxiety, (33.3%) pain/arthritis, (33.3%) insomnia, (16.7%) depression, and (25.0%) nausea/vomiting. Some patients responded that cannabis was "Somewhat helpful" in the relief of (41.7%) anxiety, (33.3%) pain/arthritis, (41.7%) insomnia, (25%%) depression and (16.7%) nausea/vomiting.”

A review of 17 high-dose oral THC studies & the tolerability of these high levels (90 mg to 210 mg per day)

Tolerability of High-Dose Oral Δ9-THC: Implications for Human Laboratory Study Design

For liver diseases, a review of the efficacy of CBD (nice chart!)

The Role of Cannabidiol in Liver Disease: A Systemic Review

For the genitourinary system, a review of 15 studies on the effects of the cannabinoids

Cannabis Use and Its Multifaceted Impact on the Genitourinary System: A Scoping Review of the Literature

And a large meta-analysis of the effects of cannabinoids in acute kidney diseases in animal models

The intervention of cannabinoid receptor in chronic and acute kidney disease animal models: a systematic review and meta-analysis

For periodontal diseases, a review of 20 studies on using the cannabinoids

Effects and clinical application of cannabinoids for the treatment of periodontal disease: a systematic review

A review of eating behaviors & the endocannabinoid system

Endocannabinoid system and eating behavior

In a rat model of Alzheimer's disease, THC lowered cognitive deficits, perhaps by its ability to increase neurogenesis (the creation of new brain cells)

Delta-9-tetrahydrocannabinol Ameliorates D-galactose/ Aluminium Chloride-Induced Alzheimer’s-Like Cognitive Deficit in Rats via Neurogenesis in their Hippocampus

In a mouse model of sleep, CBD caused its sedative & hypnotic effects through a serotonin receptor (5-HT1A) as well as increasing serotonin receptors in the hypothalamus

Cannabidiol Exerts Sedative and Hypnotic Effects in Normal and Insomnia Model Mice Through Activation of 5-HT1A Receptor

In a baby rat model of mood disorders after a stroke, CBD reduced brain damage & improved motor performance as well as helping with depressive-like behaviors

Effects of cannabidiol in post-stroke mood disorders in neonatal rats

In a mouse model of pain, linderane (the active ingredient of the traditional Chinese medicine plant Linderae radix) appeared to cause its painkilling effects via the activation of the CB2 receptor in the microglia (guardian immune cells of the brain)

Linderane Attenuates Complete Freund’s Adjuvant-Induced Pain and Anxiety in Mice by Restoring Anterior Cingulate Cortex Microglia M2 Polarization through Activating Cannabinoid 2 Receptor

In a mouse model of acute aortic dissection (your heart’s aorta just falling apart), CBD caused protective effects via inhibition of white blood cell infiltration & vascular smooth muscle cell apoptosis (programmed cellular suicide)

Cannabidiol protects against acute aortic dissection by inhibiting macrophage infiltration and PMAIP1-induced vascular smooth muscle cell apoptosis

In liver cells, CBD reduced inflammation & lowered oxidative imbalances

Cannabidiol regulates the activation of hepatic stellate cells by modulating the NOX4 and NF-κB pathways

In human skin stem cells damaged by oxidative stress, CBD lowered cell death via inhibition of ferroptosis (an iron-dependent form of cell death)

Anti-Ferroptotic Effect of Cannabidiol in Human Skin Keratinocytes Characterized by Data-Independent Acquisition-Based Proteomics


bottom of page